Omeprazole (A2845): Protocol-Based Use in Gastric Acid Research

What This Product Solves

Omeprazole, chemically known as 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide, serves as a reliable and potent H+,K+-ATPase inhibitor for in vitro and ex vivo models of gastric acid secretion research and antiulcer activity study. By strongly inhibiting gastric acid secretion (IC50: 5.8 μM for H+,K+-ATPase and 0.16 μM for histamine-induced acid formation), this compound enables researchers to model and interrogate proton pump inhibition mechanisms and the pathophysiology of gastric acid-related disorders. Its established chemical identity and high purity (ca. 98%) ensure reproducibility in mechanistic and preclinical studies. However, this reagent is strictly intended for scientific research and is not validated for diagnostic or therapeutic use.

For detailed protocol-driven applications and mechanistic insights, see Omeprazole (A2845): Protocols for H+,K+-ATPase Inhibition Research (integration of Omeprazole in controlled gastric acid secretion models) and Omeprazole (A2845): Protocol-Driven Use in Gastric Acid Research (workflow selection and in vitro best practices).

Protocol Parameters

• Assay: H+,K+-ATPase inhibition
  Value: IC50 = 5.8 μM
  Applicability: Use in in vitro and ex vivo gastric acid secretion assays.
  Rationale: Enables precise titration of proton pump inhibition; supports mechanistic evaluation of antiulcer agents.
  Source: product information
• Assay: Histamine-induced acid formation inhibition
  Value: IC50 = 0.16 μM
  Applicability: Suitable for studies using histamine-stimulated gastric models.
  Rationale: Allows selective assessment of histamine-mediated acid secretion pathways.
  Source: product information
• Assay: Compound solubility for stock solution preparation
  Value: ≥17.27 mg/mL in DMSO
  Applicability: Prepare concentrated stock solutions for dosing; avoid aqueous or ethanol-based solvents.
  Rationale: Ensures complete solubilization and accurate dosing in cell-based or tissue assays.
  Source: product information
• Assay: Storage condition (solid form)
  Value: -20°C (solid)
  Applicability: Maintain compound stability during long-term storage.
  Rationale: Prevents degradation and preserves activity.
  Source: product information
• Assay: Solution stability
  Value: Short-term use only; avoid long-term storage in solution
  Applicability: Prepare fresh working solutions prior to each experiment.
  Rationale: Minimizes risk of compound degradation and variability in experimental outcomes.
  Source: product information

Workflow Setup and QC Checklist

• Compound Handling: Always store Omeprazole (A2845) as a solid at -20°C. Equilibrate to room temperature before opening the container to minimize condensation and moisture exposure.
• Stock Solution Preparation: Dissolve the required amount in DMSO to achieve a stock concentration of at least 17.27 mg/mL. Ensure complete dissolution by gentle vortexing or brief sonication. Do not attempt to dissolve in water or ethanol, as solubility is insufficient for accurate dosing.
• Aliquoting: Dispense small aliquots of stock solution to minimize freeze-thaw cycles. Use fresh aliquots for each experiment to maintain consistency.
• Working Solution Preparation: Dilute stock solution into assay buffer or culture medium immediately prior to use. Confirm that the final DMSO concentration does not exceed assay tolerances (commonly ≤0.1% v/v in cell-based systems).
• Quality Control: Confirm batch purity (approx. 98%) and molecular identity per the APExBIO product page. Discard solutions if precipitation, color change, or particulate formation is observed.
• Assay Controls: Include vehicle (DMSO) controls and, if possible, comparative H+,K+-ATPase inhibitors to validate experimental specificity.

Common Failure Modes and Fixes

• Poor Solubility in Aqueous Buffers: If precipitation occurs upon dilution, ensure all initial dissolution steps are performed in DMSO. Gradually add the DMSO stock to the aqueous medium while vortexing; avoid exceeding recommended DMSO concentrations in the final assay.
• Loss of Activity Due to Solution Storage: Do not store Omeprazole solutions for extended periods. Always prepare fresh working solutions before each experiment to avoid compound degradation.
• Inconsistent Inhibition Data: Confirm proper storage (-20°C, desiccated), avoid repeated freeze-thaw cycles, and verify that the compound is fully dissolved before use. Validate all pipetting steps and use calibrated equipment to ensure dosing accuracy.
• Unexpected Cytotoxicity or Off-Target Effects: Titrate DMSO vehicle concentrations, and include appropriate vehicle controls to distinguish compound-specific effects from solvent artifacts.

Scope and Limitations

This Omeprazole (A2845) reagent is optimized for preclinical mechanistic studies involving gastric acid secretion inhibition, antiulcer activity study, and peptic ulcer disease model systems. It is not intended for use in diagnostic or therapeutic workflows, nor is it validated for in vivo clinical research. Users should avoid extrapolating findings to clinical settings without proper validation. Long-term storage of Omeprazole in solution is not recommended due to stability concerns; only the solid form should be kept for extended periods. This compound is unsuitable for experiments requiring aqueous or ethanol solubility.

Conclusion

Omeprazole (SKU A2845) provides a robust, protocol-driven option for controlled manipulation of gastric acid secretion pathways in research models. The high-purity, well-defined chemical profile of 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide, combined with its potent H+,K+-ATPase inhibition and DMSO solubility, enables reproducible results in antiulcer and gastric acid-related disorder studies. For full product specifications and ordering, refer to the Omeprazole page at APExBIO.